Table 2.

Association of RFS with clinicopathologic parameters of patients with EOC

ParameterHR (95% CI)P value
All data (N = 334)
 Age<50 vs. ≥501.0 (0.69–1.8)0.205
 HistotypeHGSC vs. others1.4 (0.95–2.2)0.0856
 StageEarly vs. late8.9 (5.1–15)9.25 × 10−15
 Residual tumor0 vs. >05.4 (3.6–8.2)1.68 × 10−15
0–1 vs. >14.4 (2.9–6.6)2.67 × 10−12
 Cluster1 vs. 27.4 (3.4–16)4.46 × 10−7
Early-stage (N = 182)
 Age<50 vs. ≥501.0 (0.96–1)0.892
 HistotypeHGSC vs. others1.2 × 10−8 (0–Inf)0.998
 Cluster1 vs. 29.2 (2.1–41)0.00359
Late-stage (N = 152)
 Age<50 vs. ≥501.0 (0.99–1.0)0.518
 HistotypeHGSC vs. others0.56 (0.36–0.87)0.00987
 Residual tumor0 vs. >01.9 (1.2–3.1)0.00745
0–1 vs. >11.8 (1.1–2.7)0.0112
 Cluster1 vs. 21.6 (0.64–4)0.315
  • NOTE: There were too few early-stage EOC patients with residual tumor. A definition for the significance of bold is P value of < 0.05.

  • Abbreviations: CI, confidence interval; HR, hazard ratio; Inf, infinity.